Altered serum bile acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity

Minerbi, Amir; González, Emmanuel; Brereton, Nicholas J. B.; Fitzcharles, Mary‐Ann; Chevalier, Stéphanie; Shir, Yoram

doi:10.1097/j.pain.0000000000002694

Cited by 19 publications

(12 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6). Moreover, we found alterations in secondary bile acid metabolism (decreased ursocholate in plasma and increased lithocholic acid sulphate in the feces), consistent with previous findings in fibromyalgia 4 .…”

Section: Pervasive Changes In Mice Colonized With Fibromyalgia Microb...supporting

confidence: 92%

See 1 more Smart Citation

Gut microbiota promotes pain in fibromyalgia

Cai,

Haddad,

Haddad

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Fibromyalgia is a chronic syndrome characterized by widespread pain in the absence of evident tissue injury or pathology, making it one of the most mysterious chronic pain conditions. Despite affecting 2–4% of the population, primarily women1, the cause and underlying mechanisms of fibromyalgia remain elusive, and effective targeted treatments are currently unavailable. The gut microbiota of women with fibromyalgia differs from healthy controls2,3. However, it is unknown whether changes in gut microbiota have a causal role in mediating pain and other symptoms of fibromyalgia. Here, we show that fecal microbiota transplantation (FMT) from individuals with fibromyalgia, but not from healthy controls, into germ-free mice induces persistent pain hypersensitivity. FMT from fibromyalgia patients led to a reduction in intraepidermal nerve fiber density and alterations in the peripheral immune profile, and induced activation of spinal microglia, which contributed to the development of pain in mice. Notably, the pain hypersensitivity in mice that were administered microbiota from fibromyalgia patients resolved after FMT from healthy controls. Consistent with these findings, an open-label pilot study showed that transplanting microbiota from healthy individuals to humans with fibromyalgia alleviated pain and reduced overall symptom severity. Thus, altered gut microbiota has a causal role in fibromyalgia pain, highlighting it as a promising target for therapeutic interventions.

show abstract

Section: Pervasive Changes In Mice Colonized With Fibromyalgia Microb...supporting

confidence: 92%

“…1c). Fibromyalgia is more prevalent in females, and gut microbiota composition in fibromyalgia has only been studied in women [2][3][4] ; therefore, the weekly FMTs were performed by transplanting human stool from women with fibromyalgia and age-matched healthy controls into germ-free female mice (Fig. 1a).…”

mentioning

confidence: 99%

Gut microbiota promotes pain in fibromyalgia

Cai,

Haddad,

Haddad

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…One study compared the microbiome in 77 women with fibromyalgia and 79 controls using 16S rRNA gene amplification and whole-genome sequencing. Significant differences were revealed in the rate of bacterial taxa 29 . Anti-inflammatory Faecalibacterium and Bifidobacterium species and other species that produce the antiinflammatory compound butyrate are decreased in number.…”

Section: Gut Microbiotamentioning

confidence: 97%

Is SARS-CoV-2 the only cause of long-COVID?

Pintos-Pascual¹,

Moreno-Torres²,

Ib�nez-Est�llez³

et al. 2024

AIDSRev

View full text Add to dashboard Cite

Around 10% of adults infected with SARS-CoV-2 that survive a first episode of COVID-19 appear to experience long-term clinical manifestations. The signs and symptoms of this post-acute COVID-19 syndrome (PACS) include fatigue, dyspnea, joint pain, myalgia, chest pain, cough, anosmia, dysgeusia, headache, depression, anxiety, memory loss, concentration difficulties, and insomnia. These sequelae remind the constellation of clinical manifestations previously recognized as myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS). This condition has been described following distinct infectious events, mostly acute viral illnesses. In this way, the pathophysiology of PACS might overlap with mechanisms involved in other post-infectious fatigue syndromes. The risk of PACS is more frequent in women than men. Additional host genetic factors could be involved. There is a dysregulation of multiple body organs and systems, involving the immune system, the coagulation cascade, endocrine organs, autonomic nervous system, microbiota-gut-brain axis, hypothalamic-pituitary-adrenal axis, hypothalamic-pituitary-thyroid axis, etc. Hypothetically, an abnormal response to certain infectious agents could trigger the development of post-infectious fatigue syndromes.

show abstract

“…Hierarchical clustering was used in another study to evaluate chronic pain subgroups [ 80 ]. In addition, researchers found that ML could diagnose fibromyalgia with nearly 90% accuracy using a composition of the microbiome [ 81 ]. Nearly 20 bacterial species were identified to increase or decrease among patients with fibromyalgia.…”

Section: Use-case Examplesmentioning

confidence: 99%

Enhanced Patient-Centricity: How the Biopharmaceutical Industry Is Optimizing Patient Care through AI/ML/DL

Zou

2022

Healthcare

View full text Add to dashboard Cite

Technologies utilizing cutting-edge methodologies, including artificial intelligence (AI), machine learning (ML) and deep learning (DL), present powerful opportunities to help evaluate, predict, and improve patient outcomes by drawing insights from real-world data (RWD) generated during medical care. They played a role during and following the Coronavirus Disease 2019 (COVID-19) pandemic by helping protect healthcare providers, prioritize care for vulnerable populations, predict disease trends, and find optimal therapies. Potential applications across therapeutic areas include diagnosis, disease management and patient journey mapping. Use of fit-for-purpose datasets for ML models is seeing growth and may potentially help additional enterprises develop AI strategies. However, biopharmaceutical companies often face specific challenges, including multi-setting data, system interoperability, data governance, and patient privacy requirements. There remains a need for evolving regulatory frameworks, operating models, and data governance to enable further developments and additional research. We explore recent literature and examine the hurdles faced by researchers in the biopharmaceutical industry to fully realize the promise of AI/ML/DL for patient-centric purposes.

show abstract

Altered serum bile acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity

Abstract: Supplemental Digital Content is Available in the Text.Women with fibromyalgia show significant alterations in serum bile acids and gut bile-metabolizing bacteria. These alterations are correlated with syndrome symptom severity.

Cited by 19 publications

References 86 publications

Gut microbiota promotes pain in fibromyalgia

Gut microbiota promotes pain in fibromyalgia

Is SARS-CoV-2 the only cause of long-COVID?

Enhanced Patient-Centricity: How the Biopharmaceutical Industry Is Optimizing Patient Care through AI/ML/DL

Contact Info

Product

Resources

About